Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaVax-H1N1 in healthy individuals
NCT04146623Phase 1Completed
- Sponsor
- Codagenix
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in influenza comparing CodaVax-H1N1 with Placebo (2 arms). Primary endpoints: Reactions to vaccine at 6 days, Adverse events (AEs) at 30 days and 1 more. Started May 2019; status: completed.
02
Drugs
CodaVax-H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04146623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146623.